Access to GLP-1 medications is not equally distributed. Insurance coverage gaps, prior authorization denials, Medicaid exclusions, and provider shortages mean millions of Americans who could benefit from GLP-1 therapy cannot access it. Patient advocacy organizations are working to change this — and individual patients can amplify this work.
National patient advocacy organizations provide the institutional infrastructure for GLP-1 access campaigns — lobbying Congress, publishing white papers, filing insurance regulatory comments, and mobilizing patient voices at scale. Individual GLP-1 users can amplify advocacy work by joining these organizations, attending their events, and engaging their legislative representatives through organized advocacy campaigns.
The Obesity Action Coalition is the leading national nonprofit representing individuals affected by obesity, including the rapidly growing GLP-1 user population. The OAC advocates at federal and state levels for insurance coverage of GLP-1 medications, fights weight stigma in healthcare settings, and provides patient education resources accessible nationwide. Their Your Weight Matters National Convention gathers the obesity medicine and patient community annually — offering education, advocacy training, and community connection for GLP-1 users from every US state. OAC membership gives patients direct access to legislative advocacy tools, letter-writing campaigns, and Congressional testimony opportunities. Active member networks in all 50 states make OAC the broadest-reach patient advocacy vehicle for GLP-1 access.
All 50 States | YWM Convention | Federal & State Lobbying | Member Advocacy ToolsThe ADA advocates for 37 million Americans with diabetes — the patient population for whom GLP-1 medications were originally developed and for whom coverage is most established. The ADA's advocacy priorities include maintaining and expanding GLP-1 coverage under Medicare Part D and Medicaid for diabetes indications, fighting prior authorization delays, and pushing for formulary inclusion of newer GLP-1 agents. The ADA's annual Standards of Care and policy positions carry significant weight with insurance regulators, CMS, and Congressional health committees. Local ADA chapters in every major US city engage state legislatures on GLP-1 coverage policy. Individual patients can engage ADA advocacy through their DiabetesAdvocate program.
37M Diabetes Patients | Local Chapters Nationwide | DiabetesAdvocate ProgramThe Obesity Society brings scientific credibility to GLP-1 advocacy — publishing the research evidence that advocacy organizations cite in legislative testimony and regulatory comments. Their policy positions on GLP-1 coverage for obesity treatment, issued through the ObesityWeek conference and peer-reviewed publications, help establish the evidence base that policymakers and insurers use to make coverage decisions. The Obesity Society's ABOM certification program (described below) also shapes the clinical workforce that will treat GLP-1 patients. For GLP-1 users who want to engage with the scientific side of advocacy, The Obesity Society's patient-facing resources and public policy initiatives provide meaningful engagement pathways.
Scientific Advocacy | Evidence-Based Policy | ObesityWeek ConferenceThe Alliance for Obesity Patient Empowerment (AOPE) is an emerging coalition of patient advocacy organizations, healthcare providers, and industry stakeholders focused specifically on removing systemic barriers to obesity treatment — including GLP-1 medications. Their work addresses the full spectrum of access barriers: insurance coverage gaps, prior authorization burdens, provider shortage in underserved communities, and the weight stigma that leads to underdiagnosis of obesity as a medical condition requiring treatment. AOPE coordinates advocacy across multiple stakeholder groups, amplifying the impact of patient voices at federal and state policy levels across the United States.
Multi-Stakeholder Coalition | Systemic Access Barriers | Federal PolicyThe most impactful advocacy work in the GLP-1 space is focused on insurance coverage expansion — because the $1,000+ monthly cost of GLP-1 medications without insurance makes them inaccessible to the vast majority of Americans who could benefit. Multiple legislative and regulatory campaigns are actively working to change this landscape in 2026.
As of 2026, only three US states — California, Illinois, and Louisiana — cover GLP-1 medications for weight loss (not just diabetes) under their Medicaid programs, leaving tens of millions of lower-income Americans without access to medications proven to reduce cardiovascular disease, diabetes, sleep apnea, and other obesity-related conditions. Advocacy campaigns in states including New York, Texas, Florida, Pennsylvania, Ohio, Georgia, Michigan, North Carolina, and Washington are actively pushing for Medicaid GLP-1 coverage expansion, citing long-term cost savings to state healthcare systems from prevented comorbidities. GLP-1 users in these states can engage through the OAC's state advocacy network and their individual state legislators.
3 States with Coverage in 2026 | Active Campaigns in 15+ States | OAC State NetworkThe 2023 SELECT trial's landmark finding — that semaglutide reduces major cardiovascular events by 20% in patients with existing cardiovascular disease — opened a new FDA-approved indication for Wegovy that Medicare is now required to consider for coverage. CMS (Centers for Medicare and Medicaid Services) is under sustained advocacy pressure from the ADA, OAC, and cardiovascular medicine societies to implement this coverage across Medicare Part D plans. For GLP-1 users aged 65+ or with Medicare disability coverage who have established cardiovascular disease, the SELECT indication represents the strongest case for Medicare coverage. Advocacy organizations are tracking CMS rulemaking on this issue closely in 2026.
SELECT Trial CVD Indication | CMS Rulemaking | ADA + OAC Advocacy | Medicare Part DPrior authorization (PA) requirements for GLP-1 medications — which can delay treatment by weeks or months and result in denial rates exceeding 30% — are a major target of advocacy reform efforts. The Improving Seniors' Timely Access to Care Act (federal legislation) and similar state-level PA reform bills aim to standardize and accelerate the prior authorization process for medically proven treatments including GLP-1 medications. Patient advocacy organizations including the OAC and ADA provide PA denial appeal toolkits, sample appeal letters, and physician letter templates that GLP-1 users can use immediately. Individual patients who share their PA denial experiences publicly amplify the case for reform.
PA Reform Legislation | Appeal Toolkits | Denial Rate 30%+ | Federal + State CampaignsThe Treat and Reduce Obesity Act (TREAT Act) — introduced repeatedly in Congress and gaining momentum in 2026 — would require Medicare to cover intensive behavioral therapy and FDA-approved obesity medications including GLP-1 receptor agonists for Medicare beneficiaries with obesity. With bipartisan support from Congressional members representing constituents in all 50 states, the TREAT Act represents the most significant potential legislative expansion of GLP-1 access in the Medicare population. GLP-1 users can support TREAT Act passage through the OAC's legislative action center, contacting their Congressional representatives directly, and participating in advocacy days in Washington, DC organized annually by patient advocacy organizations.
TREAT Act | Bipartisan Support | Medicare Obesity Coverage | OAC Legislative Action CenterExpanding access to GLP-1 medications also requires an adequately trained clinical workforce. Provider shortages in obesity medicine mean that even patients with insurance coverage may struggle to find qualified prescribers — particularly in rural areas and underserved communities. Clinical education programs are building the GLP-1 prescriber pipeline.
The American Board of Obesity Medicine (ABOM) certifies physicians as Diplomates in Obesity Medicine — the credential that signals specialized GLP-1 prescribing expertise to patients and insurers. Over 5,000 ABOM-certified physicians practice across the United States, with the highest concentrations in California, Texas, New York, Florida, and Illinois. ABOM certification requires passing a comprehensive examination covering GLP-1 pharmacology, obesity pathophysiology, behavioral medicine, and clinical management — ensuring a high standard of knowledge among certified prescribers. For GLP-1 users, finding an ABOM diplomate in their area provides the highest confidence in prescriber expertise. The ABOM physician finder tool is available online and covers providers in all 50 states.
5,000+ Certified Physicians | All 50 States | Physician Finder Tool | Expertise SignalThe Obesity Medicine Association offers the most comprehensive continuing medical education (CME) curriculum for GLP-1 prescribers — covering pharmacology updates from new clinical trials, practical prescribing protocols, side effect management, patient selection criteria, long-term monitoring frameworks, and the emerging science of GLP-1 combination therapies. OMA's annual conference and online CME modules serve thousands of physicians nationwide annually. For GLP-1 users, OMA CME programs directly improve the quality of care they receive — ensuring that their prescribers have current, evidence-based knowledge of the rapidly evolving GLP-1 landscape. OMA membership is open to physicians in every US state.
Annual Conference | Online CME Modules | Thousands of Physicians | Evidence UpdatesThe explosive growth of GLP-1 telehealth prescribing has created demand for specialized training programs that prepare primary care physicians, nurse practitioners, and physician assistants to safely prescribe and manage GLP-1 medications without obesity medicine specialty training. Organizations including the American Academy of Family Physicians (AAFP), American Association of Nurse Practitioners (AANP), and the OMA have developed GLP-1 prescribing training modules specifically for primary care providers. Expanding primary care GLP-1 prescribing competency is the most scalable solution to the provider shortage — allowing GLP-1 users in underserved areas to access competent prescribing through local primary care providers rather than traveling to specialist obesity medicine practices.
Primary Care Expansion | AAFP + AANP Training | Rural Access | Scalable Workforce SolutionThe OAC is active in all 50 states with particularly strong advocacy networks in California, New York, Texas, Florida, Illinois, Pennsylvania, Ohio, Georgia, North Carolina, Michigan, Virginia, Washington, Arizona, Massachusetts, and Tennessee. The ADA maintains local chapters in every major US city. Medicaid GLP-1 coverage expansion campaigns are most advanced in California, New York, Washington, Colorado, Massachusetts, and Connecticut. ABOM-certified physicians are available in all 50 states — concentrated in major metropolitan areas with growing rural telehealth presence. Congressional TREAT Act advocacy engages representatives from every US district.